Skip to main content
. 2018 Aug 13;128(9):3926–3940. doi: 10.1172/JCI96519

Figure 1. AZD6738 potentiates radiation in syngeneic CT26 tumors and promotes immunologic memory following complete responses.

Figure 1

(A) Schematic showing schedules of the ATR kinase inhibitor AZD6738 and targeted radiation (IR). AZD6738 (75 mg/kg) was administered approximately 40 minutes before IR on days 1–2 and alone on day 3. (B and C) Response of CT26 over time to treatment with AZD6738, IR, or the combination of AZD6738 plus IR. Data represent mean tumor volumes ± SEM (B) or individual tumor volumes (C) from 2 independent experiments. n per arm (mice) = 12 vehicle, 10 AZD6738, 12 IR, 14 AZD6738 + IR. **P < 0.01, unpaired, 2-tailed t test comparing change in tumor volume from day 1 to day 20 for AZD6738 + IR vs. IR. Statistical significance not shown for other time points. (D) Complete responses of CT26 tumors over time to treatment with AZD6738 plus IR. (E) Tumor growth following rechallenge of complete responder mice with CT26 cells in the contralateral flank compared with tumor growth in CT26-naive control mice. (D and E) Data represent individual tumor volumes. n per arm (mice) = 4 AZD6738 + IR complete responders, 5 naive controls.